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Cardiac fibroblasts (CF) play a key role in orchestrating the structural remodeling of the myocardium in response to injury or stress, in part through direct regulation of extracellular matrix (ECM) turnover. The matrix metalloproteinases (MMPs) are a family of over 25 zinc-dependent proteases that together have the capacity to degrade all the protein components of the ECM. Fibroblasts are a major source of several MMPs in the heart, thereby representing a viable therapeutic target for regulating ECM turnover in cardiac pathologies characterized by adverse remodeling, such as myocardial infarction, cardiomyopathy, hypertension and heart failure. This review summarizes current knowledge on the identity and regulation of MMPs expressed by CF and discusses future directions for reducing adverse myocardial remodeling by modulating the expression and/or activity of CF-derived MMPs. 

Introduction
Adverse cardiac remodeling is a major contributor to the morbidity and mortality associated with a number of cardiovascular diseases including myocardial infarction, cardiomyopathy, hypertension and heart failure (1). Cardiac fibroblasts (CF) are the most prevalent resident cell type in the heart and are integral to its physiological function as well as coordinating structural remodeling in response to cardiac injury or stress (2,3). One of the most important functions of CF in this regard is the regulation of extracellular matrix (ECM) turnover, thereby balancing synthesis and degradation of the ECM to facilitate cardiac repair following injury and compensating for reduced cardiac function. Increased ECM turnover is considered both necessary and beneficial under certain circumstances (e.g. scar formation following infarction to prevent cardiac rupture), however if unconstrained it can also become pathological (e.g. with hypertension-induced pressure overload or in regions remote from the infarct), leading to fibrosis, cardiac dysfunction and development of heart failure (1). 
Individual ECM molecules are differentially regulated resulting in altered ratios of ECM proteins (e.g. collagen I/III) and changes in matrix-matrix interactions that can have profound effects on cardiac function (4). Hence it is naive to perceive that structural remodeling of the myocardium is simply a uniform turnover of ECM components.
	The matrix metalloproteinases (MMPs) are a major class of ECM-degrading enzymes that together have the capacity to break down all the protein components of the ECM (5). The activity of MMPs is tightly regulated by their endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), hence  disruption of the MMP/TIMP ratio leads to changes in net proteolytic activity (5). In response to specific physical and chemical stimuli, CF adopt a myofibroblast phenotype  ADDIN REFMGR.CITE (2,6) and actively remodel the cardiac ECM through altered activity of MMPs and TIMPs and modulated synthesis of structural ECM molecules (collagens, laminins, fibronectin etc), in a highly temporally and spatially coordinated manner  ADDIN REFMGR.CITE (5,7). As a major source of several MMPs and TIMPs in the heart, CF thereby represent a viable therapeutic target for regulating ECM turnover in cardiac pathologies characterized by adverse remodeling. 

Matrix Metalloproteinases
Historically, the MMP family of over 25 zinc-dependent proteases have been classified according to their substrate specificity; the major classes found in the heart include collagenases (MMP-1, MMP-8, MMP-13), gelatinases (MMP-2, MMP-9), stromelysins (MMP-3, MMP-7, MMP-10) and the membrane-type MMPs (e.g. MMP 14, also known as MT1-MMP) (5). MMP activity is regulated at both transcriptional and post-transcriptional levels. In the heart, MMP transcription can be regulated by proinflammatory cytokines (e.g. TNF, IL-1), growth factors (e.g. TGF) and other bioactive molecules (e.g. angiotensin II, endothelin), as well as reactive oxygen species (ROS) and mechanical stimuli. These diverse stimuli can initiate a variety of signaling pathways culminating in activation of specific transcription factors bound to cognate response elements within the promoter regions of specific MMP genes (5). Mechanisms of post-transcriptional regulation include modulation of mRNA stability, protein translation, pro-MMP zymogen activation, trafficking, secretion and TIMP binding (5). The majority of MMPs are secreted from cells as inactive zymogens and require subsequent proteolytic cleavage (sometimes by other MMPs) for activation. In marked contrast, the membrane-type MMPs (e.g. MMPs 14-17) are activated intracellularly by members of the proprotein convertase family of proteases before insertion in the cell membrane. 
	It is important to appreciate that MMPs also have far-reaching properties that extend well beyond ECM degradation, and that many MMP substrates are non-matrix molecules  ADDIN REFMGR.CITE (7,8). For example, a major function of MMPs is to mobilize growth factors and cytokines, not only by liberating them from the ECM, but also by cleavage and dissociation of cytokine and growth factor binding proteins (8). In this capacity MMPs can contribute to local induction-activation signaling networks and elicit multiple biological effects. These are varied (e.g. modulating cell proliferation, migration, apoptosis, angiogenesis and inflammation) and complex in nature, evoking seemingly paradoxical effects (e.g. pro- or anti-inflammatory; pro- or anti-angiogenic) (9). An increasing number of novel MMP functions are now being discovered, including intracellular roles for these proteases. For example, MMP-2 is involved in proteolysis of sarcomeric and cytoskeletal proteins in cardiomyocytes under oxidative stress and may have additional biological actions in other subcellular locations including caveolae, nuclei and mitochondria (10).
	In summary, both the ECM and non-ECM aspects of MMP activity must be recognized when considering the role of MMPs in the heart. Determining the regulatory mechanisms controlling expression and activity of individual MMPs at the CF level is therefore important not only for understanding myocardial ECM turnover, but also for understanding how CF function is regulated.  

MMP Expression by Cardiac Fibroblasts
Owing to the secreted nature of most MMPs, in vivo identification of their precise cellular source is problematic, and hence the majority of the cellular expression data available on MMPs in the heart has been gathered from in vivo studies of cellular gene expression or from in vitro cell culture studies. In situ hybridization revealed MMP-1 mRNA expression localized to CF one week after MI in rats  ADDIN REFMGR.CITE (11) and in transgenic reporter mice, MMP2 and MMP9 promoter activation was evident in CF one week post-MI  ADDIN REFMGR.CITE (12). Reports on cultured CF from a range of species (human, rat, mouse, canine) have provided strong evidence for basal and/or induced expression of MMP-1, MMP-2, MMP-3, MMP-9 and MMP-14 (2,13). A small number of studies reported expression of  MMP-13 in rodent CF (2) but it was not detected at the mRNA level either basally or following IL-1 stimulation in our recent microarray study on human CF (13). In that same  study, we also determined that MMP-10 mRNA was expressed by human CF and was markedly upregulated by IL-1 (13). In one previous study it was reported that elevated plasma levels of MMP-10 were apparent in end-stage HF patients  ADDIN REFMGR.CITE (14). The authors proposed that MMP-10 may act as a novel biomarker for LV remodelling, adding to the repertoire of MMPs that fulfil this role. Other MMPs expressed in the heart and reported to be important in myocardial remodelling (e.g. MMP-7, MMP-8) appear to be expressed mainly by cardiomyocytes and infiltrating macrophages, but not by fibroblasts  ADDIN REFMGR.CITE (13,15,16). Thus, CF express only a limited subset of the MMPs known to be present in the myocardium. The main focus of our review will be on the major MMPs expressed by CF, namely MMP-1, MMP-2, MMP-3, MMP-9 and MMP-14 (summarized in Figure 1).

Regulation of MMP Expression and Activity by Cardiac Fibroblasts
Although canonical regulatory mechanisms exist, MMP expression and activity can be differentially regulated in distinct cell types  ADDIN REFMGR.CITE (17,18). Indeed, this is the case in the heart as exemplified in a side-by-side study of MMP regulation in cardiac myocytes and fibroblasts  ADDIN REFMGR.CITE (19). To develop approaches for targeting CF-derived MMPs, it is therefore important to understand the mechanisms that control MMP expression and activity in a CF-specific context.
	In addition to their historical classification by substrate preference, the MMPs can also be classified according to the structure of their gene promoter regions (18). Of those MMPs expressed by CF, the MMP1, MMP3 and MMP9 gene promoters share similar features (Figure 2), including a TATA box (at approximately -30 bp relative to transcriptional start site), an activator protein-1 (AP-1) binding site at approximately -70 bp, a second upstream AP-1 site adjacent to a PEA3 site and a distal NFB binding site (18). In contrast, the MMP2 and MMP14 gene promoters (Figure 2) lack a TATA box and contain no AP-1 sites, and have a GC box at approximately -90 bp that binds the Sp1 family of transcription factors (18). As a consequence, MMP-2 and MMP-14 expression is generally constitutive, whereas that of MMP-1, MMP-3 and MMP-9 is low under basal conditions but can be markedly induced by a range of stimuli, including proinflammatory cytokines (13).
	The activity of mature MMPs is regulated by the TIMP family of locally secreted proteins that act as endogenous MMP inhibitors. Although their principal role is considered to be that of inhibiting MMPs, TIMPs also exhibit important MMP-independent effects on cardiac remodeling (20). CF are the major source of TIMPs in the myocardium and their expression and/or activity can be modulated by chemical, physical and environmental stimuli (2). Four TIMPs have been identified, with TIMP-1 and TIMP-2 being predominant in CF  ADDIN REFMGR.CITE (13,21).
 
MMP-1 (collagenase 1)
MMP-1 cleaves fibrillar collagens (types I, II and III), as well as some other ECM proteins. Type I and III collagens account for 90% of the protein content of the cardiac ECM, and hence collagenases are extremely important for myocardial ECM turnover. The MMP1 gene is not expressed by rodents, however two murine MMP1-like genes have been described (Mmp1a and Mmp1b)  ADDIN REFMGR.CITE (22), which may explain reports of MMP-1 expression and activity in rodent models. Although not particularly well studied, MMP-1 appears to exert favorable effects on pathological cardiac remodeling. For example, cardiomyocyte-restricted overexpression of human MMP-1 in 2-month old transgenic mice inhibited pressure overload-induced cardiac fibrosis and heart failure  ADDIN REFMGR.CITE (23), indicating that inhibition of MMP-1 activity in the heart may actually exacerbate remodeling. In contrast, an earlier study using the same mice showed development of compensatory hypertrophy and increased collagen deposition in the absence of pressure overload in 1-year old animals (24). These studies indicate that cardiac overexpression of MMP-1 can be protective or detrimental and this may depend on the age and pathological state of the heart  ADDIN REFMGR.CITE (23,24). However, it does appear that broad spectrum MMP inhibitors that do not inhibit MMP-1 are nonetheless effective in reducing post-MI adverse myocardial remodeling in animal models  ADDIN REFMGR.CITE (25,26), underscoring the complexity of their functional effects. Crucially, in the PREMIER study similar MMP-1-sparing inhibitors were found to be ineffective in man  ADDIN REFMGR.CITE (27).
The MAP kinase (ERK, JNK, p38) and NFB signaling cascades are important pathways coupling inflammatory and mitogenic signals to MMP-1 transcription via activation of transcription factors bound to a number of cis elements within the MMP1 gene promoter, including AP-1, CEBP- and the Ets-family member PEA3  ADDIN REFMGR.CITE (17,18) (Figure 2). In CF from various species, MMP-1 expression has been reported to be induced by IL-1, IL-17, PDGF, BNP and hypoxia-reoxygenation (2). In human CF, the proinflammatory cytokine IL-17 stimulated MMP-1 transcription via a p38- and ERK-dependent pathway culminating in binding at the AP-1, NFB and CEBP- promoter sites  ADDIN REFMGR.CITE (28). Also in human CF, IL-1-induced MMP-1 mRNA expression was inhibited by a broad spectrum p38 inhibitor (BIRB-0796), but not by a p38/-selective inhibitor (SB203580), suggesting a role for p38/ in regulating MMP-1 expression (13). 
	Angiotensin II, a profibrotic hormone, reduced CF MMP-1 expression in a number of studies (2). Although the mechanism for this inhibitory effect is not known, it may well result from a paracrine effect as angiotensin II is a potent stimulator of TGF- production in CF (29). Subsequent increased levels of TGF-β could inhibit MMP-1 transcription via activation of the TGF- inhibitory element (TIE) repressor site within the MMP1 gene promoter  ADDIN REFMGR.CITE (30) (Figure 2).
	
MMP-2 (gelatinase A)
MMP-2 cleaves predominantly non-fibrillar collagens (e.g. collagen IV, V, VII, X), gelatin and fibronectin. Myocardial MMP-2 activity is elevated rapidly following MI or in response to pressure overload in patients and animal models alike, and is sustained for several weeks (5). Importantly it appears that CF and myofibroblasts, rather than infiltrating inflammatory cells, are the major source of MMP-2 after MI  ADDIN REFMGR.CITE (12). Gene deletion experiments suggest that MMP-2 is an important contributor to the adverse remodeling that accompanies several cardiac pathologies (5). 
The MMP2 gene promoter (Figure 2) lacks classical regulatory elements (TATA box, AP-1 sites) and hence MMP-2 is constitutively expressed by many cell types including CF, its activity being regulated primarily at the post-transcriptional level. Nevertheless, MMP-2 expression by CF can be further induced by a number of cytokines and growth factors, as well as oxidative and mechanical stress (2). Although the underlying molecular mechanisms have not been elucidated, they may relate to the presence of Sp1 binding sites in the MMP2 promoter (Figure 2). Conversely, CF MMP-2 expression can be reduced by angiotensin II (2). 
MMP-2 is activated by conversion of the latent pro-MMP-2 zymogen to the cleaved active MMP-2 by a trimolecular complex involving pro-MMP-2, MT1-MMP and TIMP-2 (10). In cultured CF, MMP-2 activity is increased by cytokines, growth factors, ROS and collagen, and MMP-2 activity is reduced by angiotensin II or hypoxia (2). The ability of  chronic hypoxia to reduce MMP-2 activity in human CF was through reduced cell surface expression of MMP-14 (MT1-MMP) (31), an effect seemingly unique to CF. In the same study, and in agreement with a previous report  ADDIN REFMGR.CITE (32), hypoxia had the opposite effect on HT-1080 fibrosarcoma cells, resulting in increased MMP-2 activity (31).
	 MicroRNAs (miRs) are small non-coding RNA molecules that negatively regulate expression of specific genes by degradation or translational repression of target mRNAs (33). MiRs act in a highly tissue- and cell type-specific manner and their roles in CF differ from those in cardiomyocytes  ADDIN REFMGR.CITE (33-35), supporting the proposition that miRs present novel and realistic therapeutic targets. MMP-2 expression has been shown to be upregulated in CF in infarcted myocardium via a mechanism involving miR-21-mediated inhibition of the phosphatase and tensin homologue PTEN (34). Interestingly, in a separate study, miR-21 was shown to stimulate the ERK pathway specifically in CF, resulting in exacerbated cardiac remodeling characterized by increased ECM turnover, including MMP-2 upregulation  ADDIN REFMGR.CITE (35). This raised the possibility that miR-21 could be an attractive therapeutic target for CF-specific modulation of MMP-2 activity. However, more recent studies have shown that miR-21 null mice exhibit normal myocardial remodeling responses, and that inhibition of miR-21 through intravenous delivery of a specific antimiR failed to prevent adverse cardiac remodeling  ADDIN REFMGR.CITE (36), thus questioning the therapeutic potential of targeting miR-21. 

MMP-9 (gelatinase B)
MMP-9 has a similar ECM substrate profile to MMP-2 (i.e. non-fibrillar collagens, gelatin, fibronectin etc). MMP-9 expression and activity is elevated rapidly following MI or in response to pressure overload in patients and animal models (5). In contrast to MMP-2, the cellular source of MMP-9 appears to be predominantly infiltrating inflammatory cells, but MMP-9 is also upregulated in CF  ADDIN REFMGR.CITE (12). Inhibiting MMP-9 expression and/or activity reduced myocardial inflammation and remodeling in a variety of animal models, suggesting that MMP-9 is a key contributor to adverse myocardial remodeling (5).
	Despite similarities in substrate specificity and function, the transcriptional regulation of MMP-2 and MMP-9 is very different due to markedly dissimilar regulatory elements in their respective gene promoters (Figure 2). The MMP9 gene promoter exhibits greater analogy to the MMP1 and MMP3 promoters, with a TATA box and AP-1, PEA3 and NFB binding sites. 
	In CF, MMP-9 expression and activity is induced by several proinflammatory cytokines and ROS (2). Although there are reports that angiotensin II can increase MMP-9 expression in human CF, it appears to decrease MMP-9 activity in murine CF (2). In human CF, a panel of pharmacological inhibitors was employed to demonstrate that TNF-induced MMP-9 expression required ERK, PI3K/AKT and NFB signaling pathways, but was p38-independent (37). A role for PI3K/AKT in TNF-induced MMP-9 expression has been further demonstrated by the inability of TNF to stimulate MMP-9 expression in CF from PI3K knockout mice  ADDIN REFMGR.CITE (19). MMP-9 induction by IL-1 was also p38-independent in human and rat CF  ADDIN REFMGR.CITE (13,38) and, in adult rat CF, IL-1-induced MMP-9 expression required activation of specific protein kinase C isoforms and subsequent ERK, JNK and NFB activation  ADDIN REFMGR.CITE (38). However, in direct contrast to this latter study, it was reported that IL-1-induced MMP-9 expression was p38-dependent in adult rat CF, but JNK/ERK-independent  ADDIN REFMGR.CITE (39). The reasons behind these discrepancies are not immediately apparent as both studies used adult rat CF and a similar panel of pharmacological inhibitors  ADDIN REFMGR.CITE (38,39). 

MMP-3 (stromelysin-1)
MMP-3 is a broad spectrum protease which cleaves many non-fibrillar collagens, laminins, gelatin and fibronectin, as well as activating several other MMPs through zymogen cleavage. The role of MMP-3 in the myocardial remodeling process is not well defined compared with MMP-2 and MMP-9. Although plasma and myocardial MMP-3 levels are elevated following MI, the functional effect of MMP-3 is not clear at present, although it does appear to play a critical regulatory role in early post-injury myocardial remodelling (40).      
	The MMP3 gene promoter has structural similarities to the MMP1 and MMP9 promoters (Figure 2), and it is therefore not surprising that MMP-3 expression is increased by similar stimuli. Although not as well studied in CF as the other MMPs, there is evidence that MMP-3 expression is increased in CF in response to treatment by IL-1 or BNP (2). In human CF, IL-1-induced MMP-3 mRNA expression occurred in a p38-dependent manner (13). In contrast, in adult rat CF, IL-1-induced MMP-3 expression was JNK- and ERK-dependent, but not p38-dependent  ADDIN REFMGR.CITE (39). These seemingly conflicting data may hint at important inter-species differences in the regulation of individual MMPs and underscore the need for cautious interpretation.

MMP-14 (MT1-MMP)
MMP-14 belongs to the family of membrane-spanning MT-MMPs and thus it can be considered to exert highly localized effects. MMP-14 has a broad range of substrates including ECM components (fibrillar collagens I, II, III, laminins, gelatin, fibronectin), MMP zymogens (pro-MMP-2, pro-MMP-13), cytokines (SDF-1, MCP-3, TGF-) and cell adhesion molecules (CD44, E-cadherin, V integrin), conferring a role as a key regulator of local induction-activation cascades (41). Moreover, MMP-14 can act as a signaling molecule in its own right and elicit changes in gene transcription through activation of integrin-like signaling pathways downstream of its cytoplasmic domain (42).
	Expression and activity of MMP-14 are increased in hearts of patients with end-stage heart failure  ADDIN REFMGR.CITE (43) and in animal models of cardiac ischemia/reperfusion injury  ADDIN REFMGR.CITE (44). A causative role for MMP-14 in this context was supported by recent transgenic mouse studies in which cardiomyocyte-specific overexpression of human MMP-14 increased adverse myocardial remodeling post-MI  ADDIN REFMGR.CITE (45,46). The myocyte-restricted nature of these studies precluded any direct assessment of the role of MMP-14 in CF, although human CF are reported to express high levels of MMP-14  ADDIN REFMGR.CITE (13,31,43). Heterozygous knockout mice with reduced MMP-14 expression were recently shown to exhibit improved post-MI survival and cardiac function and reduced adverse remodeling (46), consistent with a detrimental role for this membrane-type MMP in post-MI remodeling. 
	In contrast to most MMPs that are upregulated by inflammatory stimuli and/or downregulated by fibrotic stimuli, MMP-14 activity and expression is upregulated in CF by the profibrotic cytokine TGF  ADDIN REFMGR.CITE (47) and by collagen  ADDIN REFMGR.CITE (48) via post-transcriptional mechanisms involving upregulation of furin, a proprotein convertase that cleaves latent MMP-14 before its trafficking to the cell surface (49). -adrenergic receptor stimulation was shown to be coupled to increased MMP-14 expression in murine CF via a cAMP-dependent mechanism  ADDIN REFMGR.CITE (50). Recently, leptin was shown to induce expression and cell surface localization of MMP-14 in adult rat CF via a Rho/ROCK-dependent mechanism, in turn leading to MMP-2 activation  ADDIN REFMGR.CITE (51). In human CF, chronic hypoxia reduced expression of MMP-14 at a post-transcriptional level resulting in decreased MMP-2 activity and resultant impaired cell migration (31). 
		 
Future Directions
Understanding the roles of cardiac MMPs in development, health and disease is of key importance to the development of therapeutic strategies to control adverse remodeling. The importance of MMP inhibitors has been exemplified by their ability to modulate myocardial ECM, but implementation of clinically relevant therapies has been difficult. Challenges in designing selective metalloproteinase inhibitors include not only the identification of the enzymes critical in disease progression, but also the fact that there are more than 25 MMPs in man. Hence how to screen inhibitors for a particular enzyme or a set of enzymes in relation to a specific pathology is both demanding and complex. The use of broad spectrum or selective MMP inhibitors has been problematic.  For example, in the PREMIER study the broad spectrum oral MMP inhibitor PG-116800 failed to reduce cardiac remodeling or improve clinical outcomes in patients following MI, despite previous beneficial effects in preclinical animal studies  ADDIN REFMGR.CITE (27). The inefficacy of MMP inhibitors in the clinic may be attributable to incomplete MMP inhibition (e.g. PG-116800 does not inhibit MMP-1 or MMP-7), inhibitory effects on perceived “beneficial” MMPs, indiscriminate effects on individual cell types (e.g. myocytes and fibroblasts), the lack of control over spatial and/or temporal expression of MMPs, and also the fact that MMPs are important for a diverse range of cellular functions that are not restricted simply to ECM regulation. 
	As discussed herein, a multitude of stimuli acting through a variety of signaling pathways increase MMP expression in fibroblasts, suggesting that modulating MMP synthesis as opposed to activity could be a worthwhile aim. In this respect pharmacological intervention might target a specific stimulus per se (e.g. cytokine receptor blockade), or a component of the intracellular signaling pathway through which it operates. For example, both inhibition of stress-activated p38/JNK pathways and the AP-1 transcription factor complex hold promise for reducing MMP expression in CF  ADDIN REFMGR.CITE (52,53). Crucially, strategies that specifically target CF in a spatial and/or temporal  manner, whilst “sparing” other myocardial cell types are key considerations for the future, and some progress has been made in this direction (54).

Conclusion
Fibroblasts play a key role in regulating ECM turnover in the heart and are central to the myocardial remodeling process that underlies several cardiovascular pathologies. By understanding the molecular mechanisms regulating expression and activity of different MMPs at the level of the CF, and how this manifests itself temporally and spatially in the heart, we hope to be able to design specific therapies that protect beneficial remodeling while reducing detrimental remodeling. Further studies aimed at specifically manipulating the function of CF in vivo are clearly warranted.
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Figure 1. Regulatory stimuli affecting expression and activity of major cardiac fibroblast MMPs. Summary of known regulatory mechanisms obtained from studies on cultured CF. Based on data reviewed in (2) and updated with data from the current review  ADDIN REFMGR.CITE (28,31,34,50,51). Abbreviations: Ang II, angiotensin II; anox-reox, anoxia-reoxygenation; -AR, -adrenergic receptor; BNP, B-type natriuretic peptide; hypox-reox, hypoxia-reoxygenation; IL, interleukin; PDGF, platelet-derived growth factor; ROS, reactive oxygen species; TGF-, transforming growth factor-; TNF, tumor necrosis factor . 

Figure 2. Major transcription factor binding elements located in the promoter regions of MMP genes expressed by cardiac fibroblasts. Schematic diagram showing major transcription factor binding sites in proximal and distal regions of gene promoters for human MMPs. Note similarities between MMP1, MMP3 and MMP9 (TATA box, AP-1, PEA3, NFB) and between MMP2 and MMP14 (Sp1 sites, no TATA box or AP-1 sites). Figure adapted and modified from (18). Abbreviations: AP-1, activator protein-1; AP-2, activator protein-2; CEBP-, CCAAT/enhancer binding protein-; HIF, hypoxia-inducible factor; NFB, nuclear factor B; PEA3, polyoma enhancer A binding protein-3; SAF-1, serum amyloid A activating factor-1; SBE, STAT-binding element; Si, silencer sequence; Sp1, Specificity protein-1 binding site (GC box); Tcf-4, T-cell factor-4; TIE, TGF- inhibitory element; SPRE, stromelysin PDGF response element; TATA, TATA box.











23



